The invention encompasses syringe devices, mixing administration systems, protective packaging for syringe devices and components, and methods of protecting syringe device handlers from contents of those devices.
Preparation of medicants or medication agents and administration of such agents to an individual often involves mixing of two or more components to form the agent and subsequent delivery of the mixed medicant to the individual. The mixing of components can typically involve extraction of one component in fluid form from a vial or other container and transfer of such components into a separate container which holds another component. In particular instances, only a portion of the contents of a vial or container is to be utilized for preparing a mixture prior to administering. Accordingly, the extraction and transfer can involve precise measuring of one or more components to be mixed.
A variety of problems may occur when utilizing conventional methodology and devices for mixing and/or administering medicants to an individual. For example, where multiple components are to be mixed, extraction and transfer of one component and introduction of such component into another component can potentially expose one or both of the components to a non-sterile or contaminated environment leading to contamination of the resulting medicant. Additionally, incomplete extraction or improper measurement of one or more components can result in preparation and/or administration of an improper dosage. In particular instances, once a medicant is mixed the mixture must again be extracted from a vial or container into a syringe prior to administering to an individual. Such additional transfer can lead to additional opportunities for contamination, incomplete extraction of contents and/or inaccurate measuring of a component or the resulting medicant.
In practice, there is limited availability of sterile environments for maintaining sterility during transfer and/or mixing of components, or preparation and transfer of medicants. Additional errors can result from use of the wrong diluent to reconstitute the medication. Preparation of medicants utilizing multiple components can be tedious and time consuming due to factors such as the need to access individually packaged items such as separate vials and/or transfer devices, or to measure one or more components to be combined to form the medicant.
Another factor to be considered when preparing medicants for administration is the nature of the medicants contained in the device and/or device components. For example, agents contained within device components may be potentially harmful to handlers upon exposure. Such potentially harmful agents include but are not limited to allergens, teratogens, endocrine-disruptors, carcinogens, or otherwise toxic or potentially toxic materials. Many conventional medicant administration devices potentially expose the handler of such device to the medicants being administered or prepared during the preparation and administration processes.
It would be desirable to develop alternative methodology and systems for preparation and administration of medicants and systems to protect handlers from exposure to contents of medicant device components.
In one aspect the invention includes a syringe device mixing/administration system including a syringe barrel having a forward end and an opposing back end. The system further includes a syringe piston insertable into the back end of the syringe barrel and a fluid bag reversibly attached to the forward end of the syringe barrel. A protective film material encases the syringe barrel, the syringe piston and the fluid bag.
In one aspect the invention includes a syringe device having a syringe barrel with an internal chamber and a syringe piston having a first end insertable into the internal chamber, a second end and a stem extending from the first end to a container housing. The container housing extends to the second end of the syringe piston and is configured to house a container. At least a portion of the container housing is insertable within the internal chamber of the syringe barrel. A fluid passageway extends from the container housing through the piston stem and through the first end of the piston.
In one aspect the invention includes a method of protecting a syringe handler including providing the components of a syringe device and encasing the components in a protective film. The protective film includes one or more members of the group consisting of polypropylene (PP), polyvinyls, aluminum foil, aluminum oxide coated nylon, biaxially oriented (biax) nylon (BO nylon), biax polyethylene terephthalate (BOPET), aluminum oxide coated BOPET, polycarbonate, oriented polypropylene (OPP), biax OPP (BOPP), high density polyethylene (HDPE), medium density polyethylene (MDPE), low density polyethylene (LDPE), linear low density polyethylene (LLDPE), ethylene vinyl acetate copolymer (EVA), metallocene, ionomer, polyvinylidene chloride (PVdC), metallized PET, metallized OPP, poly(ethylene vinyl alcohol) (EVOH), coex, surlyn, silicon oxide coated BOPET, and paper. The protective film packaging can be referred to as “active” meaning it allows manipulation of the contained device components without opening of the packaging. In one embodiment the packaging film is loose to allow manipulation of the syringe components relative to one another without opening or puncturing the film.
In one aspect the invention includes a method of protecting a syringe handler including providing the components of a syringe device, encasing the components in a protective film comprising one or more members of the group consisting of polypropylene (PP), polyvinyls, aluminum foil, aluminum oxide coated nylon, biaxially oriented (biax) nylon (BO nylon), biax polyethylene terephthalate (BOPET), aluminum oxide coated BOPET, polycarbonate, oriented polypropylene (OPP), biax OPP (BOPP), high density polyethylene (HDPE), medium density polyethylene (MDPE), low density polyethylene (LDPE), linear low density polyethylene (LLDPE), ethylene vinyl acetate copolymer (EVA), metallocene, ionomer, polyvinylidene chloride (PVdC), metallized PET, metallized OPP, poly(ethylene vinyl alcohol) (EVOH), coex, surlyn, silicon oxide coated BOPET, and paper. The protective film is formed to at least partially conform to the shape of the components. The protective film is heat sealed to at least some of the components of the syringe device.
In one aspect the invention includes protective syringe device packaging that includes a laminate film of material sealed to encase the components of a syringe device containing a potentially harmful agent where the laminate film includes at least one member of the group consisting of polypropylene (PP), polyvinyls, aluminum foil, aluminum oxide coated nylon, biaxially oriented (biax) nylon (BO nylon), biax polyethylene terephthalate (BOPET), aluminum oxide coated BOPET, polycarbonate, oriented polypropylene (OPP), biax OPP (BOPP), high density polyethylene (HDPE), medium density polyethylene (MDPE), low density polyethylene (LDPE), linear low density polyethylene (LLDPE), ethylene vinyl acetate copolymer (EVA), metallocene, ionomer, polyvinylidene chloride (PVdC), metallized PET, metallized OPP, poly(ethylene vinyl alcohol) (EVOH), coex, surlyn, silicon oxide coated BOPET, and paper.
Preferred embodiments of the invention are described below with reference to the following accompanying drawings.
This disclosure of the invention is submitted in furtherance of the constitutional purposes of the U.S. Patent Laws “to promote the progress of science and useful arts” (Article 1, Section 8).
In general aspects, the invention pertains to systems utilized for mixing and/or administering medicants. Devices, components of devices, packaging, and methods of mixing and/or administration are encompassed by the invention and are depicted and described herein.
The components and methods described and exemplified herein can be utilized in conjunction with many of the devices and methods described in U.S. patent application Ser. Nos. 11/238,880 and 11/558,146, hereby incorporated by reference. It is to be understood that many of the concepts of the present invention can be utilized in conjunction with, or can be adapted to, other device configurations including conventional syringe devices and components, and those yet to be developed.
Syringe devices and other devices of the invention are not limited to particular sizes and can vary depending upon the volume of medicant to be mixed and/or administered. Accordingly, it is to be understood that the accompanying drawings are for illustrative purposes only and are not meant to limit the devices to any particular size or volumes.
Referring initially to
Mixing administration system 10 further includes a piston 200 that is insertable into the internal chamber 108 of syringe barrel 100 through second end 104 as depicted in
Piston 200 of
An enlarged view of piercing structure 260 is shown in cross-section in
Fluid passage through piston stem 206 and the piercing device is controlled by way of valve 250, which is insertable into an opening 212 in stem portion 206 across fluid passageway 208.
Vial housing 300 is shown in cross-section in
Housing 300 is depicted in
Referring again to
When mixing is desired, vial 400 can be manipulated via access through opening 310 in housing 300 and can be slid forward toward first end 202 of piston 200. Such sliding can bring vial 400 into contact with piercing structure 260 and, using sufficient force, can allow piercing of a septum of the vial by the piercing structure to establish fluid communication between the fluid channel 270 through piercing structure 260 and the vial. Once the piercing structure is engaged across the septum, the shape of the piercing structure along with the textured sidewalls assists in maintaining the positioning of the vial in the forward position within the housing.
Once fluid communication has been established between the vial and the fluid passageway, valve 250 can be repositioned to an “on” position to allow fluid communication between the vial and the syringe barrel. Piston 200 can then be slid forward into syringe barrel 100 to cause fluid transfer between chamber 108 and vial 400. Repeated forward and backward sliding motion of the piston can be utilized to mix the two components. Such mixing can be further assisted by, for example, shaking, agitating and/or swirling of the syringe system.
When sufficient mixing has occurred, the mixed medicant can be drawn into syringe chamber 108 by withdrawing syringe piston 200 to its original position. Valve 250 is then repositioned to the “closed” position to block fluid communication between syringe chamber 108 and vial housing 400. When administration is desired cap 106 can be removed to expose a needle or appropriate attachment fitting for injection by needle, IV port, etc. Administration is achieved by sliding piston 200 forward into syringe barrel 108.
Referring next to
Once cap 410 has been removed from housing 300a, vial 400 can be slid forward onto the piercing structure via access opening 310a. As illustrated by
The shape and spacing of fingers 316 is not limited to the triangular close-fit shown. For example, fingers 316 can be spaced and/or can be alternatively shaped such as rectangular, rounded, etc.
Additional aspects of housing configurations are represented in
A partial cut away view of an alternative configuration is depicted in
Referring next to
Referring next to
An alternative embodiment of a syringe mixing/administration system is depicted in
Medicant bag 500 is a bag for containing fluids and can therefore be referred to as a fluid bag. The fluid bag can be provided in an initially empty state or having an initial fluid content.
Where fluid bag 500 is provided initially containing a medicant fluid or diluent, syringe device 10 can be provided in an initial configuration having syringe piston 200 positioned such that stopper 210 is at the forward end of syringe barrel 100. Partial withdrawal of the piston can be utilized to extract fluid from bag 500 into syringe barrel 100. A vial disposed within housing 300 can be slid forward onto piercing structure (or alternate connecting structure) and valve 250 can be repositioned to an “on” position to establish fluid communication between the syringe barrel and the enclosed vial. Mixing can occur by insertion and withdrawal of the syringe piston into the syringe barrel. Syringe barrel 100 can then be removed from bag 500 in preparation for administration of the mixed medicant.
Referring next to
Utilizing the illustrated valve configuration, a first diluent or medicant component can be provided in fluid bag 500, a second component or diluent can be provided in syringe barrel 100 and a third component can be provided in medicant vial 400. If additional components are to be added, such can be achieved utilizing conduit 558 and appropriate positioning of valve 552. As depicted, valve device 550 can comprise removable fixtures for reversible attachment of syringe barrel 100 at outlet 554 and syringe and fluid bag 500 at outlet 556. Mixing and administration of the components can be achieved by appropriate positioning of valve 552.
In one aspect, the invention pertains to packaging configurations for protecting a syringe from becoming contaminated and/or for protecting the administrating person or handler from exposure to the contents of the syringe device. Protection of the administrating personnel and other device handlers becomes important when administrating or handling agents that may contain one or more potentially dangerous material such as components that may be allergens, teratagens, endocrine-disrupters, carcinogens or otherwise toxic or potentially toxic materials. The described configurations below may be utilized with the devices described herein, with devices described in the earlier filed applications that are incorporated by reference, or with conventional syringe devices and components thereof.
Referring to
Packaging 600 forms an internal compartment 610. In preferred embodiments the packaging of the invention provides a sterile internal environment to protect the device and its content from contamination. Sterilization may occur during and/or after sealing of the packaging. Terminal sterilization may be performed which can provide a final sterilization of all components (packaging and enclosed device). Terminal sterilization may involve sterilization during or after the sealing process utilizing one or more sterilization techniques including, but not limited to exposure to vaporized H2O2, gamma rays, electron beam irradiation, chemiclave (e.g. trace formaldehyde), autoclave (e.g. at a temperature of at least 121° C. for at least 21 minutes at an appropriate pressure as would be understood by one skilled in the art), etc. The method(s) utilized for terminal sterilization may depend upon the materials of the device components, drug components, the liquids present, if any, and/or the packaging materials.
Packaging 600 is preferably provided such that mixing can be completed without opening or puncturing of the packaging. Perforation 602 or a removable tear strip or other access can be provided preferably at the forward end of syringe barrel 100 to allow access to the device for administration purpose while minimizing exposure to the device contents. Such positioning can also minimize the portion of the device which is exposed to the external atmosphere. Alternatively, a perforation line or point can be provided which can be torn or otherwise penetrated by the needle cover. The packaging can then be pulled back slightly to expose the needle cover and allow administration to be performed while minimizing exposure to the device.
The protective packaging of the invention is not limited to any particular material. The packaging can be formed of a single material or from two or more materials. Referring to
Example materials which may be utilized for packaging include, but are not limited to polypropylene (PP), polyvinyls, aluminum foil, aluminum oxide coated nylon, biaxially oriented (biax) nylon (BO nylon), biax polyethylene terephthalate (BOPET), aluminum oxide coated BOPET, polycarbonate, oriented polypropylene (OPP), biax OPP (BOPP), high density polyethylene (HDPE), medium density polyethylene (MDPE), low density polyethylene (LDPE), linear low density polyethylene (LLDPE), ethylene vinyl acetate copolymer (EVA), metallocene, ionomer, polyvinylidene chloride (PVdC), metallized PET, metallized OPP, poly(ethylene vinyl alcohol) (EVOH), coex, surlyn, silicon oxide coated BOPET, paper and/or coated or uncoated TYVEK® (E. I. du Pont de Nemours and Company, Wilmington Del.). The materials utilized can depend upon the protections desired and the method of sterilization to be utilized.
It is to be understood that the packaging concepts of the invention are not limited to the devices specifically described herein or in the earlier filed applications. For example, the packaging of the invention can be used in conjunction with conventional syringes, conventional syringe systems, conventional mixing systems, conventional medicant delivery components and systems, devices and components yet to be developed.
Referring next to
Additional packaging is shown in
In particular systems a vial or container containing a medicant can be provided separately from the remaining components of the mixing administration device but can be packaged within the same protective packaging as illustrated in
With reference to
Additionally or alternatively, packaging can be attached to the device at one or more points 615. Such attachment can be achieved utilizing, for example, heat sealing, welding, ultrasonic methods or adhesives. The points of attachment are not limited to any particular location or number. Preferably, the attachments stabilize the positioning of the device during shipping and storage and can be disconnected from the device by pulling away of the packaging from the device by the user for manipulation during preparation for administration.
The mixing/administration systems of the invention can be used with ease by a variety of personnel including, for example, home care providers, battlefield or disaster relief workers, or by patients themselves with minimal risk of error or contamination. In particular embodiments, devices of the invention are provided in protective packaging that decreases the likelihood of exposure of personnel to the contents of the device. The packaging is provided to meet or exceed standards for cleanliness and sterility as documented in U.S. Pharmacopia §797.
In compliance with the statute, the invention has been described in language more or less specific as to structural and methodical features. It is to be understood, however, that the invention is not limited to the specific features shown and described, since the means herein disclosed comprise preferred forms of putting the invention into effect. The invention is, therefore, claimed in any of its forms or modifications within the proper scope of the appended claims appropriately interpreted in accordance with the doctrine of equivalents.
This application is a continuation of U.S. patent application Ser. No. 12/242,121 filed Sep. 30, 2008, which claims priority under 35 U.S.C. §119 to Provisional Patent Application No. 60/977,557, which was filed Oct. 4, 2007; and to Provisional Patent Application No. 60/988,509, which was filed Nov. 16, 2007; and to Provisional Patent Application No. 61/082,870, which was filed Jul. 23, 2008, the entirety of each of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
730054 | Sheets | Jun 1903 | A |
984037 | Sheets | Feb 1911 | A |
1100799 | Wedig | Jun 1914 | A |
1465793 | Schilling | Aug 1923 | A |
1696018 | Schelberg | Dec 1928 | A |
1707880 | Sheets | Apr 1929 | A |
2453590 | Poux | Nov 1948 | A |
2540461 | Smith | Feb 1951 | A |
2555878 | Drabicki | Jun 1951 | A |
2661740 | Hickey | Dec 1953 | A |
2677372 | Barnish | May 1954 | A |
2693186 | Ricker et al. | Nov 1954 | A |
2818999 | Miller | Jan 1958 | A |
2842124 | James | Jul 1958 | A |
2869544 | Ratcliffe et al. | Jan 1959 | A |
3052239 | Silver et al. | Sep 1962 | A |
3052240 | Silver et al. | Sep 1962 | A |
3164303 | Trautmann | Jan 1965 | A |
3342180 | Sandhage et al. | Sep 1967 | A |
3348546 | Roberts et al. | Oct 1967 | A |
3473646 | Burke | Oct 1969 | A |
3511239 | Tuschhoff | May 1970 | A |
3645268 | Capote | Feb 1972 | A |
3648704 | Jackson | Mar 1972 | A |
3659602 | Cloyd | May 1972 | A |
3841329 | Killinger | Oct 1974 | A |
3844318 | Raia et al. | Oct 1974 | A |
3938520 | Scislowicz et al. | Feb 1976 | A |
3946732 | Hurscham | Mar 1976 | A |
4014330 | Genese | Mar 1977 | A |
4031892 | Hurschman | Jun 1977 | A |
4044757 | McWhorter et al. | Aug 1977 | A |
4116240 | Guiney | Sep 1978 | A |
4142633 | Raghavachari et al. | Mar 1979 | A |
4153057 | Kobel | May 1979 | A |
4164203 | Cavanagh | Aug 1979 | A |
4166533 | Maitland et al. | Sep 1979 | A |
4191225 | Ogle | Mar 1980 | A |
4244364 | Grushkin | Jan 1981 | A |
4303069 | Cohen | Dec 1981 | A |
4328802 | Curley et al. | May 1982 | A |
4405317 | Case | Sep 1983 | A |
4411622 | Pearson | Oct 1983 | A |
4411662 | Pearson | Oct 1983 | A |
4424057 | House | Jan 1984 | A |
4464174 | Ennis | Aug 1984 | A |
4518386 | Tartaglia | May 1985 | A |
4585446 | Kempf | Apr 1986 | A |
4589879 | Pearson | May 1986 | A |
4591357 | Sneider | May 1986 | A |
4599082 | Grimard | Jul 1986 | A |
4624667 | Rutnarak | Nov 1986 | A |
4657534 | Beck et al. | Apr 1987 | A |
4685596 | Mattheis | Aug 1987 | A |
4700872 | Keyes et al. | Oct 1987 | A |
4722733 | Howson | Feb 1988 | A |
4735608 | Sardam | Apr 1988 | A |
4758231 | Haber et al. | Jul 1988 | A |
4759750 | DeVries et al. | Jul 1988 | A |
4781701 | Geprags | Nov 1988 | A |
4838855 | Lynn | Jun 1989 | A |
4861335 | Reynolds | Aug 1989 | A |
4874381 | Vetter | Oct 1989 | A |
4886495 | Reynolds | Dec 1989 | A |
4898209 | Zbed | Feb 1990 | A |
4915701 | Halkyard | Apr 1990 | A |
4969883 | Gilbert et al. | Nov 1990 | A |
4994029 | Rohrbough | Feb 1991 | A |
4997420 | Lefevre | Mar 1991 | A |
5067948 | Haber et al. | Nov 1991 | A |
5069670 | Vetter et al. | Dec 1991 | A |
5080649 | Vetter | Jan 1992 | A |
5098402 | Davis | Mar 1992 | A |
5135496 | Vetter et al. | Aug 1992 | A |
5137511 | Reynolds | Aug 1992 | A |
5139490 | Vetter et al. | Aug 1992 | A |
5147329 | Brannon | Sep 1992 | A |
5171214 | Kolber et al. | Dec 1992 | A |
5181909 | McFarlane | Jan 1993 | A |
5226900 | Bancsi et al. | Jul 1993 | A |
5247972 | Tetreault | Sep 1993 | A |
5290228 | Uemura et al. | Mar 1994 | A |
5312336 | Haber et al. | May 1994 | A |
5320603 | Vetter et al. | Jun 1994 | A |
5330426 | Kriesel et al. | Jul 1994 | A |
5334163 | Sinnett | Aug 1994 | A |
5356375 | Higley | Oct 1994 | A |
5356380 | Hoekwater et al. | Oct 1994 | A |
5364369 | Reynolds | Nov 1994 | A |
5372586 | Haber et al. | Dec 1994 | A |
5372590 | Haber et al. | Dec 1994 | A |
5393497 | Haber et al. | Feb 1995 | A |
5407070 | Bascos et al. | Apr 1995 | A |
5411489 | Pagay et al. | May 1995 | A |
5411499 | Dudar et al. | May 1995 | A |
5423751 | Harrison et al. | Jun 1995 | A |
5437648 | Graves et al. | Aug 1995 | A |
5466219 | Lynn et al. | Nov 1995 | A |
5466220 | Brenneman | Nov 1995 | A |
5470327 | Helgren et al. | Nov 1995 | A |
5472403 | Cornacchia et al. | Dec 1995 | A |
5478314 | Malenchek | Dec 1995 | A |
5478337 | Okamoto et al. | Dec 1995 | A |
5484406 | Wong et al. | Jan 1996 | A |
5489266 | Grimard | Feb 1996 | A |
5505704 | Pawelka et al. | Apr 1996 | A |
5529189 | Feldschuh | Jun 1996 | A |
5531672 | Lynn | Jul 1996 | A |
5531683 | Kriesel et al. | Jul 1996 | A |
5533994 | Meyer | Jul 1996 | A |
5549569 | Lynn et al. | Aug 1996 | A |
5566729 | Grabenkort et al. | Oct 1996 | A |
5569191 | Meyer | Oct 1996 | A |
5569193 | Hofstetter et al. | Oct 1996 | A |
5580351 | Helgren et al. | Dec 1996 | A |
5584819 | Kopfer | Dec 1996 | A |
5618268 | Raines et al. | Apr 1997 | A |
5630800 | Blank et al. | May 1997 | A |
5637100 | Sudo | Jun 1997 | A |
5647845 | Haber et al. | Jul 1997 | A |
5653686 | Coulter et al. | Aug 1997 | A |
5674195 | Truthan | Oct 1997 | A |
5685866 | Lopez | Nov 1997 | A |
5722950 | Fujita et al. | Mar 1998 | A |
5738655 | Vallelunga et al. | Apr 1998 | A |
5766147 | Sancoff et al. | Jun 1998 | A |
5769825 | Lynn | Jun 1998 | A |
5772665 | Glad et al. | Jun 1998 | A |
5776125 | Dudar et al. | Jul 1998 | A |
5785701 | Sams et al. | Jul 1998 | A |
5795337 | Grimard | Aug 1998 | A |
5807323 | Kriesel et al. | Sep 1998 | A |
5827262 | Neftel et al. | Oct 1998 | A |
5833653 | Vetter et al. | Nov 1998 | A |
5842326 | Wolf | Dec 1998 | A |
5897527 | Tsukada | Apr 1999 | A |
5928215 | Caizza et al. | Jul 1999 | A |
RE36273 | Brannon | Aug 1999 | E |
5976115 | Parris et al. | Nov 1999 | A |
5989227 | Vetter et al. | Nov 1999 | A |
6027472 | Kriesel et al. | Feb 2000 | A |
6065270 | Reinhard et al. | May 2000 | A |
6099511 | Devos et al. | Aug 2000 | A |
6149623 | Reynolds | Nov 2000 | A |
6267154 | Felicelli et al. | Jul 2001 | B1 |
6280430 | Neftel et al. | Aug 2001 | B1 |
6319225 | Sugita et al. | Nov 2001 | B1 |
6349850 | Cheikh | Feb 2002 | B1 |
6358236 | DeFoggi et al. | Mar 2002 | B1 |
6364866 | Furr et al. | Apr 2002 | B1 |
6379328 | Mac Clay | Apr 2002 | B1 |
6379340 | Zinger et al. | Apr 2002 | B1 |
6391014 | Silverman | May 2002 | B1 |
6478788 | Aneas | Nov 2002 | B1 |
6478808 | Nowakowski | Nov 2002 | B2 |
6488651 | Morris et al. | Dec 2002 | B1 |
6491665 | Vetter et al. | Dec 2002 | B1 |
6527738 | Jones et al. | Mar 2003 | B1 |
6544233 | Fukui et al. | Apr 2003 | B1 |
6576224 | Osbakken et al. | Jun 2003 | B1 |
6591876 | Safabash | Jul 2003 | B2 |
6599264 | Erni et al. | Jul 2003 | B1 |
6599273 | Lopez | Jul 2003 | B1 |
6602223 | Szapiro et al. | Aug 2003 | B2 |
6626309 | Jansen et al. | Sep 2003 | B1 |
6638244 | Reynolds | Oct 2003 | B1 |
6650929 | Nemoto et al. | Nov 2003 | B1 |
6681946 | Jansen et al. | Jan 2004 | B1 |
6716193 | Neftel | Apr 2004 | B1 |
6729370 | Norton et al. | May 2004 | B2 |
6743214 | Heil et al. | Jun 2004 | B2 |
6802828 | Reynolds | Oct 2004 | B2 |
6808511 | Pond | Oct 2004 | B2 |
6817987 | Vetter et al. | Nov 2004 | B2 |
6852103 | Fowles et al. | Feb 2005 | B2 |
6912800 | Vetter et al. | Jul 2005 | B2 |
7036288 | Vetter et al. | May 2006 | B2 |
7074216 | Fowles et al. | Jul 2006 | B2 |
7077835 | Fathallah | Jul 2006 | B2 |
7081109 | Tighe et al. | Jul 2006 | B2 |
7134782 | Coffeen et al. | Nov 2006 | B2 |
7134974 | Almasian et al. | Nov 2006 | B2 |
7137974 | Almasian et al. | Nov 2006 | B2 |
7161488 | Frasch | Jan 2007 | B2 |
7213702 | Takimoto et al. | May 2007 | B2 |
7331941 | Vetter et al. | Feb 2008 | B2 |
7338477 | Meyer et al. | Mar 2008 | B2 |
7452344 | Jorgensen et al. | Nov 2008 | B2 |
7470257 | Norton et al. | Dec 2008 | B2 |
7470258 | Barker et al. | Dec 2008 | B2 |
7553304 | Neftel | Jun 2009 | B2 |
7713239 | Uber, III et al. | May 2010 | B2 |
7731678 | Tennican et al. | Jun 2010 | B2 |
7736353 | Reynolds | Jun 2010 | B2 |
7753891 | Tennican et al. | Jul 2010 | B2 |
7824373 | Kim et al. | Nov 2010 | B2 |
20020002354 | Vetter et al. | Jan 2002 | A1 |
20020022804 | Connolly et al. | Feb 2002 | A1 |
20020061281 | Osbakken et al. | May 2002 | A1 |
20020065490 | Heinz et al. | May 2002 | A1 |
20020068896 | Robinson et al. | Jun 2002 | A1 |
20020087118 | Reynolds et al. | Jul 2002 | A1 |
20020177819 | Barker et al. | Nov 2002 | A1 |
20030069545 | Arm | Apr 2003 | A1 |
20030114798 | Langley et al. | Jun 2003 | A1 |
20030225378 | Wilkie et al. | Dec 2003 | A1 |
20040122345 | Muller | Jun 2004 | A1 |
20040232171 | Bobst | Nov 2004 | A1 |
20060027523 | Van Lintel et al. | Feb 2006 | A1 |
20060178642 | Gillespie et al. | Aug 2006 | A1 |
20060275336 | Du Plessis | Dec 2006 | A1 |
20060278588 | Woodell-May | Dec 2006 | A1 |
20070249996 | Tennican et al. | Oct 2007 | A1 |
20080015496 | Hamedi-Sangsari | Jan 2008 | A1 |
Number | Date | Country |
---|---|---|
2513165 | Aug 2004 | CA |
06839806 | Feb 2011 | EP |
01-131671 | May 1989 | JP |
3009662 | Feb 1995 | JP |
WO 9629113 | Sep 1996 | WO |
WO 9937233 | Jul 1999 | WO |
WO 0013723 | Mar 2000 | WO |
WO 0141666 | Jun 2001 | WO |
WO 2004064706 | Aug 2004 | WO |
WO 2006044236 | Apr 2006 | WO |
PCTUS05036071 | Sep 2006 | WO |
PCTUS05036071 | Jan 2007 | WO |
WO 2005036071 | Jan 2007 | WO |
PCTUS06060745 | Apr 2008 | WO |
PCTUS08078774 | Dec 2008 | WO |
PCTUS08078774 | Dec 2010 | WO |
WO 2008078774 | Dec 2010 | WO |
2006060745 | Jan 2011 | WO |
PCTUS06060745 | Jan 2011 | WO |
Entry |
---|
PCT/US05/036071 Search Report, Sep. 8, 2006, Hyprotek, Inc. |
PCT/US05/036071Written Opinion, Sep. 8, 2006, Hyprotek, Inc. |
PCT/US06/060745 Search Report, Apr. 11, 2008, Hyprotek, Inc. |
PCT/US06/060745Written Opinion, Apr. 11, 2008, Hyprotek, Inc. |
PCT/US08/078774 Search Report, Dec. 17, 2008, Hyprotek, Inc. |
PCT/US08/078774Written Opinion, Dec. 17, 2008, Hyprotek, Inc. |
http://www.duoject.com/flash/duoject.html (2 pages). |
http://www.life-assist.com/setfinder/preslit.html; ICU Medical/Setfinder Needle Free Products, pp. 1-5. |
U.S. Appl. No. 11/751,410, filed May 21, 2007, Tennican et al. |
Clip'n Ject [retrieved online Nov. 9, 2005]: http://www.westpharma.com/products/clip—n—Ject.asp?1=0. |
Debioclip Manual [retrieved online Nov. 9, 2005]: http://www.debiotech.com/products/drugdd/debioclip.html. |
http://www.duoject.com/flash/duoject.html (2 pages), retrieved online Mar. 2, 2006. |
http://www.life-assist.com/setfinder/preslit.html; ICU Medical/Setfinder Needle Free Products, pp. 1-5, retrieved online Apr. 11, 2005. |
Number | Date | Country | |
---|---|---|---|
20110272310 A1 | Nov 2011 | US |
Number | Date | Country | |
---|---|---|---|
60977557 | Oct 2007 | US | |
60988509 | Nov 2007 | US | |
61082870 | Jul 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12242121 | Sep 2008 | US |
Child | 13183955 | US |